Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Anti-FLT3 CAR- T Cell (TAA05 Cell Injection) in the Treatment of Relapsed/ Refractory Acute Myeloid Leukemia
Conditions
Interventions
Fludarabine + Cyclophosphamide + TAA05 Cell Injection
Locations
1
China
Wuhan Union Hospital
Wuhan, Hubei, China
Start Date
June 14, 2022
Primary Completion Date
June 14, 2025
Completion Date
June 14, 2027
Last Updated
July 6, 2022
NCT05564390
NCT03050268
NCT07320235
NCT06439199
NCT06782542
NCT05886049
Lead Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions